 |
市场调查报告书
商品编码
1392001
范科尼贫血治疗药物市场：依治疗类型、年龄层、阶段、地区Fanconi Anemia Drug Market, By Treatment Type, By Age Group, By Disease Stage, By Geography |
||||||
2023年全球范可尼贫血治疗市场估计为5.744亿美元，预计到2030年将达到8.136亿美元，2023年至2030年复合年增长率为5.1%。
| 报告范围 | 报告详情 | ||
|---|---|---|---|
| 基准年 | 2022年 | 2023年市场规模 | 5.744亿美元 |
| 实绩资料 | 2018-2021 | 预测期 | 2023-2030 |
| 预测期复合年增长率 | 5.10% | 2030年市场规模预测 | 8.136 亿美元 |
范可尼贫血治疗旨在治疗范可尼贫血的症状和潜在的遗传异常，范可尼贫血是一种罕见的遗传性疾病，其特征是骨髓衰竭、出生缺陷和癌症风险增加。或药物治疗和目前正在研究的治疗方法。许多器官系统都受到范可尼贫血的影响。范可尼贫血是由缺陷基因引起的，该基因会损害细胞并阻止细胞修復受损的 DNA。它几乎影响身体的每个器官。也称为遗传性再生障碍性贫血。
市场动态：
科学研究和分子机制知识的不断进步预计将推动预测期内范可尼贫血治疗药物市场的成长。此外，在预测期内，未满足的医疗需求将继续推动范可尼贫血治疗市场的成长。这一因素推动了研究和开发配合措施，以寻找控制和治疗 FA 的有效疗法。在预测期内，疾病修正治疗的开拓可能为全球范可尼贫血治疗市场创造新的机会。我们有机会创造能够解决与 FA 相关的遗传变化和分子机制的缓解疾病药物。例如，2022年5月17日，生物技术公司Jasper Therapeutics, Inc.宣布将加入史丹佛大学医学院确定性和治疗医学中心（CDCM），研究JPS191作为调理剂治疗范可尼贫血。宣布资助研究中第一位患者的给药。根据该协议，史丹佛大学医学院正在对 JSP191 进行一项 1/2 期临床试验 (NCT04784052)，用于治疗患有骨髓衰竭且需要非兄弟姐妹供体同种异体移植的范可尼贫血患者。
本研究的主要特点
- 本报告对全球范可尼贫血治疗药物市场进行了详细分析，并提供了以2022年为基准年的预测期（2023-2030年）的市场规模和年复合成长率（CAGR%）。
- 它还揭示了各个细分市场的潜在商机，并为该市场说明了一系列有吸引力的投资提案。
- 它还提供了有关市场驱动因素、抑制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的重要考察。
- 它根据公司亮点、产品系列、主要亮点、财务实绩和策略等参数，介绍了全球范可尼贫血治疗药物市场的主要企业。
- 该报告的见解使行销人员和公司负责人能够就未来的产品发布、升级、市场扩张和行销策略做出明智的资讯。
- 全球范可尼贫血治疗药物市场报告迎合了该行业的各种相关人员，如投资者、供应商、产品製造商、经销商、新进业者和财务分析师。
- 相关人员可以透过用于分析全球范可尼贫血治疗药物市场的各种策略矩阵来促进他们的决策。
目录
第1章研究目的与前提
- 研究目标
- 假设
- 简称
第2章市场展望
- 报告说明
- 市场定义和范围
- 执行摘要
- Coherent Opportunity Map（COM）
第3章市场动态、法规及趋势分析
- 市场动态
- 促进因素
- 科学研究和分子机制理解的不断进步
- 大量未满足的医疗需求
- 抑制因素
- 缺乏公认的治疗方法
- 机会
- 疾病修正治疗的开发
- 影响分析
- 主要亮点
- 监管场景
- 产品发布/核准
- PEST分析
- 波特的分析
- 併购场景
第4章全球范可尼贫血治疗药物市场 -冠状病毒（COVID-19）大流行的影响
- 新型冠状病毒感染疾病（COVID-19）的流行病学
- 供需面分析
- 经济影响
第5章全球范可尼贫血治疗药物市场，依治疗类型，2018-2030
- 造血生长因子
- 基因治疗
- 干细胞移植
- 其他治疗方法
第6章全球范可尼贫血治疗市场，依年龄组，2018-2030
- 儿童患者
- 成年患者
第7章全球范可尼贫血治疗市场，依阶段，2018-2030
- 阶段
- 晚期
第8章全球范可尼贫血治疗药物市场，按地区，2018-2030
- 北美洲
- 美国
- 加拿大
- 拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲
- 欧洲
- 德国
- 英国
- 西班牙
- 法国
- 义大利
- 俄罗斯
- 其他欧洲国家
- 亚太地区
- 中国
- 印度
- 日本
- 澳洲
- 韩国
- ASEAN
- 其他亚太地区
- 中东
- GCC
- 以色列
- 其他中东地区
- 非洲
- 南非
- 北非
- 中部非洲
第9章竞争形势
- Foresee Pharmaceuticals Co., Ltd.
- Rocket Pharmaceuticals Inc.
- Amgen
- Novartis AG
- Gilead Sciences, Inc.（Kite Pharma, Inc.）
- Celgene Corporation（Juno Therapeutics）
- Spark Therapeutics
- UniQure NV
- Bluebird Bio, Inc.
- PTC Therapeutics
- Orchard Therapeutics Limited
- GlaxoSmithKline Plc.
- Aurora Biopharma, Inc.
- Pfizer, Inc.
- Autolus Therapeutics
第10章章
- 调查方法
- 关于出版商
Global fanconi anemia drug market is estimated to be valued at US$ 574.4 Mn in 2023, and is expected to reach US$ 813.6 Mn by 2030, exhibiting a compound annual growth rate (CAGR) of 5.1% from 2023 to 2030.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2022 | Market Size in 2023: | US$ 574.4 Mn |
| Historical Data for: | 2018 to 2021 | Forecast Period: | 2023 - 2030 |
| Forecast Period 2023 to 2030 CAGR: | 5.10% | 2030 Value Projection: | US$ 813.6 Mn |
The fanconi anemia drugs are pharmaceutical therapies and treatments that have been created or are currently being researched with the goal of treating the symptoms and underlying genetic abnormalities of fanconi anemia, a rare genetic disorder that is marked by bone marrow failure, congenital defects, and an increased risk of developing cancer. Numerous organ systems are impacted by fanconi anemia. Fanconi anemia results from a defective gene that harms cells, and prevents them from mending damaged DNA. It has an impact on practically all body organs. It is also known as aplastic anemia that is hereditary.
Market Dynamics:
Continuous advancements in scientific research and knowledge about molecular mechanisms are expected to drive the global fanconi anemia drug market growth over the forecast period. Substantial unmet medical need will also continue to fuel growth of the global fanconi anemia drug market over the forecast period. This element motivates efforts in research and development to find efficient therapeutics for the control and treatment of FA. Development of disease-modifying therapies will create new opportunities for the global fanconi anemia drug market over the forecast period. There are opportunities for the creation of disease-modifying medications that can deal with the genetic alterations and molecular mechanisms connected to FA. For instance, on May 17, 2022, Jasper Therapeutics, Inc., a biotechnology company, announced the dosing of the first patient in its sponsored research of the Center for Definitive and Curative Medicine (CDCM) at the Stanford University School of Medicine for the study of JPS191 as a conditioning agent in the treatment of Fanconi Anemia. In accordance with the sponsored research agreement, Stanford Medicine is conducting a Phase 1/2 clinical trial (NCT04784052) utilizing JSP191 to treat Fanconi Anemia patients in bone marrow failure requiring allogeneic transplant with non-sibling donors.
Key features of the study:
- This report provides in-depth analysis of the global fanconi anemia drug market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2023-2030), considering 2022 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global fanconi anemia drug market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Foresee Pharmaceuticals Co., Ltd., Rocket Pharmaceuticals Inc., Amgen, Novartis AG, Gilead Sciences, Inc. (Kite Pharma, Inc.), Celgene Corporation (Juno Therapeutics), Spark Therapeutics, UniQure N.V, Bluebird Bio, Inc., PTC Therapeutics, Orchard Therapeutics Limited, GlaxoSmithKline Plc., Aurora Biopharma, Inc., Pfizer, Inc. and Autolus Therapeutics
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- Global fanconi anemia drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global fanconi anemia drug market
Detailed Segmentation:
- By Treatment Type:
- Hematopoietic Growth Factors
- Gene Therapy
- Stem Cell Transplantation
- Other Therapies
- By Age Group:
- Pediatric Patients
- Adult Patients
- By Disease Stage:
- Early-stage Disease
- Advanced-stage Disease
- By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
- Company Profiles:
- Foresee Pharmaceuticals Co., Ltd.
- Rocket Pharmaceuticals Inc.
- Amgen
- Novartis AG
- Gilead Sciences, Inc. (Kite Pharma, Inc.)
- Celgene Corporation (Juno Therapeutics)
- Spark Therapeutics
- UniQure N.V
- Bluebird Bio, Inc.
- PTC Therapeutics
- Orchard Therapeutics Limited
- GlaxoSmithKline Plc
- Aurora Biopharma, Inc.
- Pfizer, Inc.
- Autolus Therapeutics
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Fanconi Anemia Drug, By Treatment Type
- Market Fanconi Anemia Drug, By Age Group
- Market Fanconi Anemia Drug, By Disease Stage
- Market Fanconi Anemia Drug, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Continuous advancements in scientific research and understanding of the molecular mechanisms
- Substantial unmet medical need
- Restraints
- Lack of recognized therapies
- Opportunities
- Development of Disease-Modifying Therapies
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
4. Global Fanconi Anemia Drug Market - Impact of Coronavirus (COVID-19) Pandemic
- COVID-19 Epidemiology
- Supply Side and Demand Side Analysis
- Economic Impact
5. Global Fanconi Anemia Drug Market, By Treatment Type, 2018-2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019-2030
- Segment Trends
- Hematopoietic Growth Factors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Gene Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Stem Cell Transplantation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Other Therapies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
6. Global Fanconi Anemia Drug Market, By Age Group, 2018-2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019-2030
- Segment Trends
- Pediatric Patients
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Adult Patients
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
7. Global Fanconi Anemia Drug Market, By Disease Stage, 2018-2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019-2030
- Segment Trends
- Early-stage Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Advanced-stage Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
8. Global Fanconi Anemia Drug Market, By Region, 2018-2030, (US$ Mn)
- Introduction
- Market Share Analysis, By Region, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, For Region, 2018 -2030
- Country Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Stage, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Mn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Stage, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Mn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Stage, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Mn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Stage, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Stage, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Stage, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Mn)
- South Africa
- North Africa
- Central Africa
9. Competitive Landscape
- Foresee Pharmaceuticals Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Rocket Pharmaceuticals Inc.
- Amgen
- Novartis AG
- Gilead Sciences, Inc. (Kite Pharma, Inc.)
- Celgene Corporation (Juno Therapeutics)
- Spark Therapeutics
- UniQure N.V
- Bluebird Bio, Inc.
- PTC Therapeutics
- Orchard Therapeutics Limited
- GlaxoSmithKline Plc.
- Aurora Biopharma, Inc.
- Pfizer, Inc.
- Autolus Therapeutics
- Analyst Views
10. Section
- Research Methodology
- About us
